Table 3 Clinical and laboratory data before and after PTX
Ref | Author, year | N cases | Age (years) | PTH pre/post (pg/ml) | BP pre/post (mmHg) | Other | Antihypertensive treatment |
|---|---|---|---|---|---|---|---|
6 | Lin, 2013 | 30* | 53.3 ± 13.3 | 1012 ± 247 vs 136 ± 157 (P < 0.001) | Sys:148 ± 17 vs 139 ± 18 Dia: 79 ± 10 vs 74 ± 12 (P < 0.009; < 0.007) | Ca, PO4, Ca x Ph, hemoglobin improved after PTX; | No data |
7 | Shih, 2013 | 21 | 57.4 ± 12 | 1011(611–1402) vs 19.1 (10.3–61.6) 6 mos (P < 0.001) | Sys:138.9 ± 16.4 vs 121.2 ± 18.6 Dia: 77.6 ± 8.3 vs 69.2 ± 9.8 (P < 0.001) | Improved heart function; reduced intradialytic hypotension. | Pre PTX: 1.14 ± 1.11 drugs Post PTX: 0.67 ± 1.2 drugs |
8 | Leiba, 2013 | 3 | 45, 46, 30 | 2408 / 6 7000 / 2000 3642 / 16–30 | Sys: 140; 180–200; 175–210 vs 60; 50; 100 Dia: 90; 100; 120 vs 40; 30; 60 | Pre PTX Case 1: no data Case 2: clonidine, amlodipine, atenolol doxazosin Case 3: clonidine, minoxidil | |
9 | De Santo, 2010 | 40 | 55.8 ± 6.8 | 1.299.6 / 46.8 | Sys: 139 vs 135 Dia: 83 vs 81 (P < 0.001, P = 0.001) | treated Pre PTX 100% Post PTX 72.5% | |
10 | Esposito, 2008 | 16 | 54.6 ± 13 | 1434 ± 400 vs 40.3 ± 37.4 | Sys: 138.9 ± 18.39 vs 130.8 ± 23.47 (P = 0.05) Dia: 83.1 ± 11.84 vs 78.8 ± 6.7 (P = 0.05) | Beneficial effects of PTX on sleep disorders. | Pre PTX, all on combined treatment** Post PTX: 12 /16 on antihypertensive drugs. |
11 | Chow, 2003 | 12 | 50 ± 11 | 243.6 ± 22.6 vs 9.2 ± 13.4 | Sys: 141 ± 16 vs 145 ± 16 Dia: 77 ± 10 vs 80 ± 10 P = NS | No effect on pruritus; regression of left ventricular hypertrophy | Pre PTX: ACEi: 2 (17%); Post PTX: ACEi 1 (8%) P = NS |
12 | Almirall, 2002 | 17 | NS | 1056 ± 803 (pre-PTX) | Sys: 140.5 ± 17.3 vs 141 ± 20.8 Dia: 81.6 ± 9.3 vs 80.4 ± 9.3 P = NS | No effect on heart rate, dry body weight | No difference after PTX |
13 | Saatci, 2002 | 13 | 41.38 ± 10.85 | 1210.25 ± 262.2 vs 172.88 ± 155.88 | Sys: 126 ± 25.9 vs 102.8 ± 20.5 (P < 0.01) Dia: 74 ± 16.46 vs 64.44 ± 15.89 (P < 0.04) | Decline in BP, if PTH < 200 ng/l. Benefits to triglyceride levels | Groups similar at baseline |
14 | Coen G, 2001 | 45 | 56 ± 11 | 1313.4 ± 1.004.1 vs 214.2 ± 357.4 (1 week-6 months) | Sys: 134.7 ± 29.2 vs 125.9 ± 25.8 Dia: 81.6 ± 14.6 vs 77.8 ± 12.9 (P < 0.001) | No difference between subtotal or total PTX; increased erythropoietin level | Anti-hypertensive number and doses reduced post PTX |